>2024-2028 guidance above market expectations - At its CMD, Qiagen's new mid-term guidance was clearly in the focus. For the first time, the company provided a top-line guidance (2024-2028 CAGR of 7%) that reflects above-market growth rates for all five strategic pillars and came in above consensus estimates of 6.6% for this period. At the same time, the company forecasts an adjusted operating profit margin of at least 31% CER in 2028 compared to market expectations o...
>Headwinds for PCR testing systems - Qiagen yesterday evening announced it is discontinuing the NeuMoDx integrated PCR testing system, given market development trends for these product lines following the Covid-19 pandemic and changing customer needs for integrated PCR-based clinical molecular testing systems.NeuMoDx sales slumped by 60% since 2021 - During our GIS conference in January 2024, management already stated it would address the problems for...
BHP's bid for Anglo American has confirmed interest from miners in copper in the context of increasingly challenged production and difficulties in fully completing projects. Anglo’s (Neutral) prospects in copper are now better valued and this is also the case for BHP (Neutral vs Underperform) although not so for Rio Tinto (Outperform vs Neutral). Downstream, Nexans and Montana Aerospace are our Top Picks (Outperform) vs Aurubis, Rexel and Prysmian (Neutral). - ...
L’offre de BHP sur Anglo American a confirmé l’intérêt des minières pour le cuivre dans un contexte de tensions croissantes sur la production et de difficultés à faire aboutir les projets. Les perspectives d’Anglo (Neutre) dans le cuivre sont désormais mieux valorisées, c’est aussi le cas de BHP (Neutre vs Sous-performance) mais pas encore assez, selon nous, sur Rio Tinto (Surperformance vs Neutre). En aval, Nexans et Montana Aerospace sont nos valeurs préférées (Surperformance) vs Au...
>Solid Q1 figures above expectations and guidance - Qiagen reported a set of solid Q1 results. Sales came in at $459m, above our ($ 456m) and the consensus estimates ($ 458m). Y-o-y, sales declined as expected by 5%, reflecting challenging macro demand trends and predominantly burdened by declining instrument sales (-10% to $50m). Looking at CER sales of $ 462m, Q1 2024 came in some 1.5% as guided by the company ($ 455m).Adjusted operating income of $ 118m was sl...
>Strong Q4 drives 2023 results above expectations - Thanks to a strong Q4 with sales CER up by 1% to $ 503m, despite a -43% sales decrease in Covid-19 product groups, Qiagen met its FY 2023 sales guidance of € 1.97bn - in contrast to our and the consensus expectations. The group also over-delivered on its CER adj. EPS target of $ 2.07 and achieved $ 2.09, vs our estimates of $ 2.06 and consensus of $ 2.05. The high 2023 revenue growth in non-Covid product groups (CER ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.